TY - JOUR
T1 - Epidermal cell proliferation and promoting ability of phorbol esters
AU - Slaga, Thomas J.
AU - Viaje, Aurora
N1 - Funding Information:
I Received January 15, 1976; accepted April 16, 1976. 2 Supported in part by Public Health Service grants CAI3155 and CAI7605 from the National Cancer Institute. 3 Fred Hutchinson Cancer Research Center, 1102 Columbia St., Seattle, Wash. 98104. 4 Present address.' Biology Division, Post Office Box Y, Oak Ridge National Laboratory, Oak Ridge, Tenn. 37830,
PY - 1976/11
Y1 - 1976/11
N2 - Dose-response relationships on the abilities of several phorbol ester tumor promoters to promote skin tumors after 7, 12-dimethylbenz[a]anthracene initiation and to bring about edema, inflammation, and epidermal hyperplasia were determined in female Charles River CD-1 mice. The promoting ability of the potent synthetic promoter, phorbol-12, 13-dioctanoate (PdiC8), was determined over a dose range of 0.1-10 μg/application. Administration of PdiC8 two times weekly at dosages of 4, 6, 8, and 10 μ gave little variation in tumor response. A dose-dependent tumor response occurred at doses of 1-4 μg PdiC8. Only 1 papilloma was observed when PdiC8 was given twice weekly at a dose of 0.1 or 0.5 μg. A similar dose-response relation was observed for the ability of PdiC8 to stimulate epidermal hyperplasia. Investigations of other phorbol esters revealed an excellent correlation between their promoting ability and their ability to induce epidermal hyperplasia; however, that was not the case for compounds outside the phorbol ester series (i.e., acetic acid, cantharidin, and ethylphenylpropiolate).
AB - Dose-response relationships on the abilities of several phorbol ester tumor promoters to promote skin tumors after 7, 12-dimethylbenz[a]anthracene initiation and to bring about edema, inflammation, and epidermal hyperplasia were determined in female Charles River CD-1 mice. The promoting ability of the potent synthetic promoter, phorbol-12, 13-dioctanoate (PdiC8), was determined over a dose range of 0.1-10 μg/application. Administration of PdiC8 two times weekly at dosages of 4, 6, 8, and 10 μ gave little variation in tumor response. A dose-dependent tumor response occurred at doses of 1-4 μg PdiC8. Only 1 papilloma was observed when PdiC8 was given twice weekly at a dose of 0.1 or 0.5 μg. A similar dose-response relation was observed for the ability of PdiC8 to stimulate epidermal hyperplasia. Investigations of other phorbol esters revealed an excellent correlation between their promoting ability and their ability to induce epidermal hyperplasia; however, that was not the case for compounds outside the phorbol ester series (i.e., acetic acid, cantharidin, and ethylphenylpropiolate).
UR - http://www.scopus.com/inward/record.url?scp=0017175792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017175792&partnerID=8YFLogxK
U2 - 10.1093/jnci/57.5.1145
DO - 10.1093/jnci/57.5.1145
M3 - Article
C2 - 826651
AN - SCOPUS:0017175792
VL - 57
SP - 1145
EP - 1149
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 5
ER -